Fig. 5

Hepatocellular carcinoma (HCC) follow-up under myo-inositol trispyrophosphate (ITPP) treatment (red) versus control group (blue) of hepatocyte-specific Trim24-null mice. a Follow-up of tumor volumes by micro-CT-scan imaging. Logarithmic scale was employed in order to cover the entire volume range. No significant difference was observed between the tumor volumes in the ITPP group and in the control group at any time point. Before treatment started (12 to 15–16 months), there was a significant progression in tumor volume in both groups (*black, p = 0.043). At 3 and 9 months after the treatment started (15–16 to 18–19 months), the tumor burden in live animals was in significant progression in the control group (*blue) and in ITPP group (*red). b Tumor doubling time (TDT), on the basis of tumor volumes obtained by micro-CT. No difference was observed in TDT between the ITPP group and the control group, at any time point. In the ITPP group, mild tumor growth acceleration was observed at 3 months of treatment with significant deceleration at 9 months (p = 0.008). c Survival curves. Median survival interval was 296 days in the ITPP group and 223 days in the control group corresponding to a 2-month prolongation of life span. Log-rank comparison demonstrated improved survival in the ITPP group (p = 0.0027). d Gene expression level in tumor (full bars) and non-tumor livers (motif bars) in sacrificed hepatocyte-specific Trim24-null mice, at the end of the follow-up period. Data were expressed as average fold expression +/− standard deviation. In the control group, the p53 expression level was significantly higher in tumor over non-tumor liver (*blue, p < 0.05)